Screener
Royalty Pharma RPRX Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeOther.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense | 93,617 | 68,668 | 187,339 | 133,929 |
| (Gains)/losses on equity securities | (69,156) | 30,553 | (48,990) | 76,431 |
| Losses on available for sale debt securities | 34,880 | 27,420 | 41,560 | 30,701 |
| Interest income | (5,127) | (8,327) | (11,356) | (19,617) |
| Other non-operating expenses, net | 1,496 | 1,543 | 3,697 | 4,604 |
| Total other expense, net | 51,633 | 117,164 | 146,415 | 216,912 |
| Consolidated net income before tax | 81,486 | 92,635 | 549,741 | 527,068 |
| Income tax expense | — | — | — | — |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's interest income?
- Royalty Pharma (RPRX) reported interest income of $5.13M in Q2 2026.
- How has Royalty Pharma's interest income changed year-over-year?
- Royalty Pharma's interest income decreased by 38.4% year-over-year, from $8.33M to $5.13M.
- What is the long-term trend for Royalty Pharma's interest income?
- Over 4 years (2021 to 2025), Royalty Pharma's interest income has grown at a -11.0% compound annual growth rate (CAGR), from $53.54M to $33.59M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Royalty Pharma's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude